Determining When Home Health Visits Are Better Than Site Visits in Clinical Trials

In the evolving landscape of decentralized clinical trials (DCTs), sponsors and investigators increasingly leverage home health visits as a substitute or complement to traditional site visits. These in-home interactions allow trained professionals to conduct study procedures in a patient’s residence, reducing burden and increasing retention. But when is it appropriate to choose home health over site visits? This tutorial outlines clear criteria, best practices, and regulatory insights for making that decision.

Why the Shift Toward Home Health in DCTs?

The traditional site visit model can introduce logistical, financial, and emotional burdens for participants. Home health visits offer:

• Reduced travel and time off work
• Improved access for rural or mobility-limited patients
• Increased retention and protocol adherence
• Continuity of care during public health crises (e.g., COVID-19)
• Enhanced patient satisfaction and real-world trial feasibility

This aligns with modern, GMP-compliant patient-centric approaches that emphasize engagement and convenience.

When Home Health Visits Are Appropriate:

Home visits are most suitable in trials where procedures can be safely conducted outside a clinical setting. Typical scenarios include:

1. Routine blood draws and vitals: Easily managed by licensed nurses.
2. Questionnaire-based assessments: Especially when conducted electronically or via tablet.
3. Follow-up visits: When no complex interventions are needed.
4. Long-term extension studies: To reduce the burden of travel for committed participants.
5. Geographically dispersed participants: Where travel to sites is impractical.

When to Retain Site-Based Visits:

Despite flexibility, some procedures still require clinical settings:

• Imaging (MRI, CT, ultrasound)
• Specialist assessments (e.g., ophthalmology, dermatology)
• PK blood draws with precise timing
• Complex drug infusions or biopsies
• First-dose monitoring for safety

Regulators such as the CDSCO emphasize that patient safety must guide all such decisions.

Evaluating Protocol Fit for Home Health:

Use a decision matrix during protocol development to identify:

• Which visits can shift to home based on risk-benefit
• What assessments can be decentralized
• Which patients are eligible (e.g., tech-savvy, stable condition)

This approach supports SOP compliance in pharma and avoids protocol deviations later.

Hybrid Models: Balancing Home and Site Visits

Many trials adopt a hybrid model with:

• Initial site visits for screening, baseline, or drug initiation
• Home visits for interim follow-ups, assessments, and retention
• Final site visits for endpoint measurements or final drug accountability

This model optimizes resource use while ensuring data quality and regulatory compliance across all touchpoints.

Operational Considerations for Home Visits:

Shifting to home-based care requires robust operational planning:

• Vendor qualification and nurse credential verification
• Clear visit schedule and logistics coordination
• Training home nurses in stability testing protocols
• Documentation tools (paper, eSource, or mobile app)
• Backup plans for missed visits or emergencies

Consistency across global locations requires alignment with regulatory and ethical guidelines.

Documentation and Oversight:

Each home visit must be properly documented with:

• Visit report and nurse notes
• Sample collection logs (if applicable)
• Adverse event documentation
• Signed informed consent for in-home procedures
• Compliance with validation protocols for any collected data/devices

All documentation must be audit-ready and stored in the eTMF system.

Patient-Centric Benefits and Feedback:

Patients report high satisfaction when home health options are available. Key benefits include:

• Flexibility in scheduling
• Fewer missed visits due to illness or obligations
• Improved adherence to dosing schedules
• Higher overall engagement

Collecting patient feedback post-visit is critical for continuous improvement and supports pharma regulatory compliance.

Common Challenges with Home Health Execution:

• Scheduling conflicts: Mitigated by flexible visit windows and communication tools
• Inconsistent nurse quality: Addressed through robust vendor training programs
• Protocol deviations: Minimized through clear SOPs and retraining
• Data inconsistency: Resolved with centralized monitoring platforms

Best Practices for Choosing Home Over Site Visits:

1. Conduct a visit-by-visit feasibility assessment
2. Integrate home visits in protocol and ICF from the outset
3. Define clear eligibility for participants receiving home visits
4. Align documentation and monitoring SOPs accordingly
5. Review feedback from past DCTs to refine visit models

Conclusion:

Home health visits are not a one-size-fits-all solution, but they are a powerful option for enhancing trial accessibility, efficiency, and patient satisfaction. The decision to shift from site-based to home-based procedures should be grounded in risk assessment, protocol design, and operational readiness. When implemented thoughtfully, home visits can become a cornerstone of future-ready, decentralized trials.